Please login to the form below

Not currently logged in
Email:
Password:

RotaTeq

This page shows the latest RotaTeq news and features for those working in and with pharma, biotech and healthcare.

Sanofi unit takes low-cost rotavirus vaccine into phase III

Sanofi unit takes low-cost rotavirus vaccine into phase III

and Merck &Co's RotaTeq which, while effective, are still unaffordable for many countries battling with the infection. ... III trials, promising to make it available at around one-tenth the price of Rotarix and RotaTeq.

Latest news

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics